Arca
Skip to content
Tools
Tools

Hypoglycemia

Drug research and approvals for hypoglycemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 70 studies of hypoglycemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and FDA has 1 approved and 6 open orphan designations naming it.

  • Recruiting worldwide: 70
  • Trials authorized in Canada: 4
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 70 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 3

  • GlucagonGlucagon receptor agonist
  • DiazoxidePotassium channel, inwardly rectifying, subfamily J, member 11 opener
  • DonislecelSomatic cell supplemental therapy

Phase 3 2

Phase 2 8

Phase 1 or earlier 12 of 15

How its trials ended

599 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 150 whose ending is known, 49% met their primary endpoint, 4% missed it and 47% stopped early.

  • Completed, result not reported30150%
  • Ongoing9316%
  • Met its primary endpoint7312%
  • Status unknown559%
  • Stopped: other or unclear407%
  • Stopped: enrollment or feasibility132%
  • Missed its primary endpoint61%
  • Stopped: lack of efficacy61%
  • Stopped: funding61%
  • Stopped: sponsor or business decision41%
  • Stopped: safety2<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Aug 27, 2021A phase 1/2 study to evaluate the safety, tolerability, and efficacy of VX-880 in subjects who have type 1 diabetes mellitus with impaired hypoglycemic…VX-880Vertex PharmaceuticalsOngoing
Jan 16, 2018G-pen tm(glucagon injection) compared to lilly glucagon (glucagon for injection [rdna origin]) for induced hypoglycemia rescue in adult patients with T1D: a…GlucagonXeris PharmaceuticalsClosed
Dec 1, 2017An open-label, first-in-human, study evaluating the safety,tolerability, and efficacy of VC-02 combination product in subjects with type 1 diabetes mellitus…VC-02 (VC-02-20, VC-02-300)Vertex PharmaceuticalsOngoing
Oct 26, 2017A one-year, multicenter, non-interventional, follow-up, safety study in subjects previously implanted with VC-02 combination productVC-02Vertex PharmaceuticalsOngoing

FDA orphan designations

Approved first, then open designations, newest first
Jun 28, 2023LantidraTreatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe…CellTrans Inc.Approved
Nov 20, 2024ErsodetugTreatment of hypoglycemia due to tumor-associated hyperinsulinismRezolute Inc.Designated
Jan 24, 2018Glucagon (ready-to-use)Treatment of hyperinsulinemic hypoglycemiaXeris Pharmaceuticals, Inc.Designated
Aug 10, 2017DasiglucagonTreatment and prevention of hypoglycemia in patients with congenital hyperinsulinismZealand Pharma A/SDesignated
Dec 8, 2016AvexitideTreatment of hyperinsulinemic hypoglycemiaAmylyx Pharmaceuticals, Inc.Designated
Sep 25, 2014Glucagon infusionPrevention of chronic, severe hypoglycemia related to congential hyperinsulinismXeris Pharmaceuticals, Inc.Designated
Dec 5, 2012GlucagonPrevention of hypoglycemia in the congenital hyperinsulinism populationBiodel, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.